Current Opinion in HIV and AIDS was launched in 2006. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of HIV and AIDS are divided into nine sections that are reviewed once a year. Each section is assigned one or two Section Editors, leading authorities in the area, who identify the most important topics at that time. Here we are pleased to introduce the Editors for the journal and the Section Editors for this issue.
David A. Cooper
David A. Cooper AO FAA is Scientia Professor of Medicine and Director of the Kirby Institute at the University of New South Wales, Sydney, Australia. The Kirby Institute is funded by the Commonwealth Department of Health and Ageing to conduct research into blood-borne viruses including HIV and viral hepatitis in Australia with the ultimate aim of reducing the burden of disease for the affected communities.
The major responsibilities of the Kirby Institute are the epidemiology and surveillance of blood-borne viruses in Australia, including research aspects and the coordination and conduct of clinical trials of innovative therapies and vaccines for HIV and viral hepatitis, as well as an active clinical research program with particular emphasis on HIV infection, viral hepatitis and sexually-transmitted infections.
In addition to the Kirby Institute, Professor Cooper is a physician in the Immunology/HIV/Infectious Diseases Clinical Services Unit at St Vincent's Hospital, Sydney, Australia, one of the largest inpatient and outpatient services for the treatment of HIV disease in Australia. He is also Director of the St Vincent's Hospital Centre for Applied Medical Research. Professor Cooper is an author on over 750 published scientific papers and is on the editorial boards of several international journals.
Internationally, Professor Cooper is recognized as a leading HIV clinician and clinical investigator. He is a past President of the International AIDS Society. He is a Director of HIVNAT, a clinical research and trials collaboration based at the Thai Red Cross AIDS Research Centre at the Chulalongkorn University Hospital in Bangkok, Thailand. He is actively involved in strategic studies of antiretroviral therapy for HIV infection in the developed and developing world as well as studies of HIV vaccines and chemoprophylaxis.
Professor Giuseppe Pantaleo was born June 17, 1956 in Bari, Italy. In 1980, he received his degree in medicine with full marks and honors, and in 1983, he became board certified in clinical hematology.
His scientific career in the field of immunology began in 1983 working on the development of a limiting dilution cloning system which was critical for the subsequent studies aimed at the phenotypic and functional characterization of circulating T lymphocytes. From 1985 to 1987 he was amongst the pioneers in the delineation of the molecular and biochemical mechanisms involved in signal transduction in human T lymphocytes.
In 1989, Professor Pantaleo joined the Laboratory of Immunoregulation, NIAID, NIH. He was the first to demonstrate the defective clonogenic potential of CD8+ T lymphocytes and the selective defect of HIV-specific cytotoxic T lymphocytes. He then studied the relationship between immune response and viral reservoirs in different anatomic compartments. He demonstrated that lymphoid organs function as a major reservoir for HIV, and that active virus replication occurs in lymphoid organs throughout the course of HIV disease including the prolonged period of clinical latency. These findings have completely changed the clinical and therapeutic management of HIV infection. In the following years, Professor Pantaleo has continued to provide important contributions to the understanding the immunopathogenesis of HIV infection. Amongst these it is noteworthy to mention the delineation of the virologic and immunologic events associated with primary HIV infection, and the observation that the proportion of CD8+ T cells involved in antiviral immune response was substantially higher compared to what was previously estimated.
Since 1997 he has pioneered the field of immune-based intervention in HIV infection and he has been part of a European program for the development of a vaccine against HIV-AIDS. Since 2005, he is leading the Poxvirus T-cell Vaccine Discovery Consortium, an international program to develop an HIV vaccine supported by the Bill and Melinda Gates Foundation.
Professor Pantaleo is author and co-author of about 250 publications in international scientific journals, he is on the editorial boards of several international journals and serves as ad hoc reviewers for several international journals.
Professor Pantaleo is Professor of Medicine and Chief of the Division of Immunology and Allergy (IAL) and of the Laboratory of AIDS Immunopathogenesis at the Centre Hospitalier Universitaire Vaudois, University of Lausanne, Switzerland. Since 2007, he has also been Executive Director of the Swiss Vaccine Research Institute. Since 2009, he has been a member of the WHO Vaccine Program scientific committee and a member of the science committee of the Global HIV Vaccine Enterprise.
Jason V. Baker
Dr Jason V. Baker is an Associate Professor of Medicine at the University of Minnesota, USA, and practices Clinical Infectious Diseases and HIV Medicine at Hennepin County Medical Center (HCMC); an urban safety-net hospital that provides primary HIV care to over 1700 persons in Minneapolis, Minnesota, USA. He completed his post-secondary education at University of Wisconsin (BS 1996; MD 2001), and internal medicine training at Oregon Health & Science University (OHSU; 2001–2004). He then completed a clinical and research fellowship in infectious diseases, and obtained a Master of Science in clinical research, at the University of Minnesota, USA, (2004–2007).
His research focuses on long-term non-AIDS defining complications, such as premature cardiovascular disease, among HIV-positive persons. His recent contributions include describing the consequences of incomplete immune recovery and persistent immune activation for subclinical vascular disease and non-AIDS clinical event risk. Dr Baker conducts pathogenesis studies and translational clinical trials on novel treatment and prevention strategies at the HCMC HIV clinic, supported by the National Institutes of Health (NIH). He has also established productive collaborations with multi-center networks including the CDC-funded SUN Study (Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy) and the NIH-funded INSIGHT group (International Network for Strategic Initiatives in Global HIV Trials). Dr Baker is currently a member of the INSIGHT Scientific Steering Committee, co-chair for a cardiovascular disease substudy for the early HIV treatment trial ‘START’ (Strategic Timing of AntiRetroviral Therapy), and serves on the editorial panel for HIV Medicine.
Caroline A. Sabin
Professor Caroline A. Sabin is Professor of Medical Statistics and Epidemiology at University College London (UCL), UK. She completed her first degree in statistics at the University of Bath, and this was followed by an MSc in medical statistics and information technology from the University of Leicester (awarded in 1991) and a PhD in epidemiology at UCL (awarded in 1995).
Her first position at the Royal Free Hospital in London, UK, was as a research statistician working on the Royal Free Hospital Haemophilia Cohort, an observational study of 111 men with haemophilia infected with HIV. Since then, she has worked for many years on the analysis of large observational HIV databases with particular interests in describing the natural history of infection and identifying prognostic markers for disease progression, in describing response to antiretroviral therapy and identifying factors associated with this, and in describing the frequency of and factors associated with adverse events of antiretroviral therapy. In 2000, she initiated the UK Collaborative HIV Cohort (UK CHIC) Study, a major multicentre study of more than 50,000 HIV-infected individuals in the UK, and has been the principal investigator for the study since this time. She is the principal statistician for the D:A:D (Data collection on Adverse events of anti-HIV Drugs) study, a large international multi-cohort study which aims to describe the relationship between antiretroviral drugs, cardiovascular disease and other serious non-AIDS events. She is also closely involved with many other large HIV cohort studies and collaborations, both in the UK and abroad, including the CASCADE Collaboration and the European Union-funded EuroCoord Network of Excellence.
Professor Sabin presents regularly on the benefits and limitations of cohort studies, particularly when making treatment comparisons. She is the author of around 400 original research articles in the field, is joint editor of HIV Clinical Trials, a specialist Editor or a member of the Editorial Committee for several other major international journals (both general medicine and HIV focused), a member of the British HIV Association (BHIVA) Executive Committee, and a scientific committee member for several international HIV conferences. She has sat on and chaired many data safety and monitoring boards for completed and ongoing randomised trials.